Swine Vaccines Market

Swine Vaccines Market Size

The global swine vaccines market was valued at USD 1.5 billion in 2024. The market is expected to grow from USD 1.6 billion in 2025 to USD 2.7 billion in 2034, at a CAGR of 6.1% during the forecast period, according to the latest report published by Global Market Insights Inc. Strong market growth can be attributed to the rising global consumption and production of pork and pork products. Pork is one of the most consumed meats worldwide, which increases the need to ensure the health and productivity of swine herds.

For instance, pork accounts for a significant portion (34%) of global meat consumption. Current pork consumption stands at about 131,040 kilotons, with an expected rise to about 131,500 kilotons by 2031. This demand underscores the importance of biosecurity and disease prevention measures, thereby driving the need for swine vaccines. Thus, to ensure animal health and reach production goals, swine producers are placing a growing importance on vaccination protocols and vaccines.

Another key factor influencing the swine vaccines market is the rising incidence of infectious diseases in pigs, such as Porcine Reproductive and Respiratory Syndrome (PRRS), Classical Swine Fever (CSF), and African Swine Fever (ASF). Porcine reproductive and respiratory syndrome (PRRS) caused an estimated USD 1.2 billion per year in lost production in the U.S. pork industry from 2016 to 2020, an 80% increase from a decade earlier, according to a new analysis by an Iowa State University expert. Such disease outbreaks have been responsible for significant loss of life, declines in productivity, and, consequently, substantial economic losses. As a response, governments have increased their surveillance and monitoring, funding research, and using vaccination as a prevention strategy, thereby driving market growth.

Swine vaccines are biological products that stimulate the pig’s immune system to recognize and fight against specific pathogens, including viruses, bacteria, and other microorganisms that infect pigs. Leading players in the global swine vaccine market include companies such as Zoetis, Merck Animal Health, Boehringer Ingelheim, Ceva Santé Animale, and Elanco Animal Health. These companies invest significantly in R&D, innovations, technological enhancements, and strategic partnerships, thereby driving the growth. Their strong global distribution networks enable them to expand market reach and drive the adoption of advanced vaccine solutions worldwide.

The swine vaccines market was valued at USD 1.3 billion in 2021 and reached USD 1.4 billion by 2023. Recurring outbreaks of diseases like African Swine Fever (ASF) and PRRS increased the adoption of preventive health measures, forcing producers to adopt comprehensive vaccination strategies. At the same time, stricter regulations on the overuse of antibiotics in livestock encouraged the broader use of vaccines as safer, long-term disease control tools. Emerging markets, especially in the Asia-Pacific, played a critical role in market expansion due to rising pork demand and the scaling up of commercial pig farming. This period also saw stronger government involvement in disease monitoring and vaccination programs, further reinforcing the role of vaccines in ensuring herd health and food security.

Swine Vaccines Market Trends

• The rapid expansion of the global livestock industry to meet the growing demand for animal protein, driven by rising populations, urbanization, and changing dietary preferences, is a key factor driving the global swine vaccines market.
  
• Pork is one of the most consumed meats worldwide. For example, the OECD-FAO Agricultural Outlook projects global pork demand rising from approximately 110.5 million tons (2019-21 average) to 128.9 million tons by 2031, with Asian demand increasing from 61.4 to 76 million tons, representing a 24% increase.
  
• With the intensification of swine production for improving efficiency and yields, swine producers are also giving much emphasis to preventive healthcare measures that protect herd health and performance. This intensification is the direct driver for swine vaccine requirements, as the vaccines are key to minimizing the risk for disease occurrence that would have serious effects on the survival of animals as well as financial yields.
  
• Moreover, food security has emerged as a critical concern for many nations, especially in regions with a high reliance on pork as a protein source. Any disruption in swine production due to infectious diseases can cause severe supply chain imbalances, pushing up meat prices and straining food availability.
  
• In such cases, vaccines are seen as a key defense mechanism to ensure stable pork production by minimizing losses from diseases such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and classical swine fever.
  
• Thus, maintaining herd health through vaccination programs directly supports global food security initiatives.
  
• Also, technological advances in vaccine development have positively influenced the market demand.
  
• For instance, Merck Animal Health's Sequivity platform uses a next-generation RNA particle technology to create rapid, custom, and herd-specific prescription vaccines for animals, primarily food-producing livestock. This platform allows for the creation of custom vaccines in as little as 10-16 weeks, enabling quick responses to evolving disease challenges like swine influenza, rotavirus, and porcine circovirus.
  
• Lastly, immunization campaigns supported by the government and regulatory bodies are also propelling the swine vaccine market.
  

Swine Vaccines Market Analysis

Based on type, the market is segmented into live attenuated vaccines, inactivated/killed vaccines, viral vector vaccines, mRNA vaccines, and other vaccines. The inactivated/killed vaccines segment accounted for a share of 57.6% and was valued at USD 862.4 million in 2024 and is poised to witness growth over the coming years.

• The inactivated or killed vaccines are known for their proven safety and stability and hence are a vaccine of choice among producers.
  
• Their longer shelf life and ease of storage also make them ideal for large-scale vaccination programs, particularly in regions with established cold chain infrastructure.
  
• As a result, inactivated vaccines continue to be a preferred choice for controlling common swine diseases globally.
  
• The live attenuated vaccines segment, on the other hand, secured a significant market share of 34.4% in 2024 and is anticipated to grow at a CAGR of 6.4% over the forecast years.
  
• These vaccines provide strong, long-lasting, and broad immune responses against multiple swine diseases.
  
• A key driver of their adoption is their proven efficacy in controlling high-impact swine diseases such as porcine reproductive and respiratory syndrome (PRRS) and swine influenza, which continue to pose significant challenges to herd health and productivity worldwide.
  
• The rapid onset of immunity provided by live attenuated vaccines is highly valuable in intensive pig farming operations, where disease outbreaks can spread quickly and cause major economic losses.
  

Based on application, the swine vaccines market is classified into bacterial infections, viral infections, parasitic infections, and other applications. The viral infections segment accounted for USD 990.6 million in 2024 and is anticipated to grow at a CAGR of 6.3% during the forecast period.

• The viral infections segment is primarily driven by the widespread prevalence and economic burden of viral diseases such as porcine reproductive and respiratory syndrome (PRRS), classical swine fever (CSF), swine influenza, and porcine epidemic diarrhea (PED).
  
• These infections are highly contagious and can cause significant mortality, reduced growth performance, reproductive failure, and financial losses for swine producers worldwide.
  
• The high transmissibility and rapid spread of these viral infections in densely populated farms make vaccination the most effective preventive measure, driving their significant market share.
  

Based on route of administration, the swine vaccines market is classified into injection vaccines, oral vaccines, and immersion/spray vaccines. The injection vaccines segment accounted for the highest market revenue of USD 1.1 billion in 2024 and is expected to reach USD 2 billion by the end of 2034.

• Injection vaccines are preferred due to their proven effectiveness in delivering a precise dose directly into the animal’s system. They offer strong, long-lasting immunity and are widely used in both preventive and emergency vaccination programs.
  
• Additionally, the availability of both inactivated and live attenuated vaccines in injectable form offers flexibility for use depending on the disease profile and farm requirements.
  
• Moreover, advances in needle-free injection technologies are reducing stress and injury to animals while improving biosecurity standards, thereby further encouraging adoption.
  
• On the other hand, the oral vaccines segment is anticipated to witness rapid growth at a CAGR of 6.5%.
  
• High growth of the oral vaccines segment is due to their ease of administration, reduced stress on animals, and suitability for mass immunization.
  
• As innovations improve the stability and effectiveness of oral formulations, their adoption is expected to rise rapidly, particularly in regions with limited veterinary infrastructure.
  

Based on the distribution channel, the swine vaccines market is categorized into veterinary hospital pharmacies, retail pharmacies, and e-commerce. The veterinary hospital pharmacies segment is expected to reach USD 2.1 billion by 2034. The e-commerce segment, on the other hand, is anticipated to witness rapid growth at a 6.6% CAGR between 2025 – 2034. Increased digital adoption, convenience, and wider product accessibility are major factors driving segmental growth.

• Veterinary hospital pharmacies are a key distribution channel in the swine vaccines market due to their direct access to livestock producers and veterinarians.
  
• These pharmacies not only supply vaccines but also provide expert guidance on vaccine administration and herd health management, ensuring proper usage.
  
• Their reliability, professional oversight, and integration with animal healthcare services make them a preferred choice for vaccine procurement.
  

North America Swine Vaccines Market

North America dominates the global market with a market size of USD 650.8 million in 2024 and is anticipated to reach USD 1.1 billion by 2034, growing at a CAGR of 5.6% between 2025 - 2034.

• North America dominates the global market due to a combination of advanced livestock management practices, robust veterinary healthcare infrastructure, and strong demand for high-quality pork production.
  
• The region has one of the largest commercial swine production bases, particularly in the U.S., where pork remains a critical component of both domestic consumption and export.
  
• Additionally, the presence of leading animal health companies and frequent outbreaks of swine diseases like PRRS have further driven vaccine demand, solidifying North America's dominant position in the global market.
  

The U.S. swine vaccines market was valued at USD 529.6 million and USD 553.3 million in 2021 and 2022, respectively. The market size reached USD 606 million in 2024, growing from USD 578.7 million in 2023.

• The U.S. holds a significant market share in the swine vaccines industry, supported by its large commercial pig farming industry and strong government initiatives promoting animal healthcare.
  
• According to the USDA, the U.S. is one of the top pork producers globally, with over 70 million hogs reported in recent years, driving substantial demand for effective disease control measures.
  
• Government programs and regulations, such as the National Pork Board’s emphasis on biosecurity and vaccination, along with investments in disease surveillance and vaccine development, further bolster vaccine adoption and market growth in the country.
  

Europe Swine Vaccines Market

Europe market accounted for USD 407.8 million in 2024 and is anticipated to show lucrative growth over the forecast period.

• Europe holds a strong position in the swine vaccines industry owing to its robust livestock industry.
  
• For example, as per the European Commission, Europe produces 20% of the world’s pork.
  
• To protect this vital industry, European countries enforce strict regulations and disease control measures aimed at preventing outbreaks like African Swine Fever, which has affected several regions in recent years.
  
• These efforts have made vaccination a key tool for farmers, leading to increased adoption across the continent. As a result, Europe remains a major player influencing the global swine vaccine market.
  

Germany dominates the Europe swine vaccines market, showcasing strong growth potential.

• Germany holds a notable share of the European market, mostly due to its large and advanced pig production industry, robust veterinary infrastructure, and a strong emphasis on animal health and biosecurity.
  
• As one of the top pork producers in Europe, Germany has a consistently high demand for vaccines to prevent diseases such as swine influenza, PRRS, and classical swine fever. This demand is supported by advanced diagnostic capabilities, government-backed disease control programs, and close collaboration between farmers, veterinarians, and pharmaceutical companies.
  
• Additionally, Germany's leadership in biotechnology and veterinary R&D contributes to the availability of high-quality, innovative vaccines, further solidifying its dominant position in the regional market.
  

Asia Pacific Swine Vaccines Market

The Asia Pacific market is projected to grow at a CAGR of 6.8%, reflecting increasing demand for disease prevention and herd health management across the region. This growth is largely influenced by the scale of pig farming operations and the impact of infectious diseases on livestock productivity.

China swine vaccines market is estimated to grow with a significant CAGR in the Asia Pacific market.

• China plays a central role in this expansion of the Asia Pacific swine vaccines industry. For instance, as of April 2025, the country had over 427 million pigs, making it the largest pig-rearing nation globally, according to Statista.
  
• A 2025 study by The Korean Society of Veterinary Science further indicates that Landrace pigs in China account for approximately 50% of the global pig population, underscoring the country’s dominance in swine production.
  
• Such a vast population requires extensive health management systems, including vaccination programs, to maintain productivity and prevent disease outbreaks.
  

Latin American Swine Vaccines Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.

• Brazil is experiencing significant growth in the swine vaccines industry, fueled by its status as one of the world’s leading pork producers with a large and intensive pig farming industry.
  
• The country faces ongoing challenges from diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS) and Classical Swine Fever, which drive strong demand for effective vaccines.
  
• Supportive government policies, investment in animal health infrastructure, and increasing adoption of modern farming practices further boost vaccine uptake.
  

Middle East and Africa Swine Vaccines Market

South Africa market is expected to experience substantial growth in the Middle East and Africa swine vaccines industry in 2024.

• South Africa is experiencing significant growth in the Middle East and Africa market due to increasing investments in animal health, heightened awareness of disease prevention, and government initiatives aimed at controlling livestock diseases.
  
• The country’s proactive approach to tackling outbreaks such as African Swine Fever and foot-and-mouth disease has driven demand for effective vaccines, while improvements in veterinary infrastructure and supply chains have supported market expansion.
  

Swine Vaccines Market Share

The competitive landscape of the swine vaccines industry is characterized by the presence of several established global players alongside emerging specialized companies. The market is highly consolidated with top players such as Boehringer Ingelheim, Merck & Co., Inc., Ceva, Elanco Animal Health Incorporated, and Zoetis accounting for 95% of the global swine vaccines market. By investing in cutting-edge immunological research, including mRNA technologies and precision vaccine formulations, these companies aim to enhance disease prevention and support better herd management.

Strategic collaborations with veterinary institutions, academic researchers, and agri-tech partners further strengthen their capabilities. Through ongoing R&D, mergers, and acquisitions, these industry leaders are expanding access to high-quality swine vaccines and reinforcing their competitive position in the global swine vaccine market.

Swine Vaccines Market Companies

Prominent players operating in the swine vaccines industry are as mentioned below:

• Addison Biological Laboratory
• Bioveta, a.s.
• Boehringer Ingelheim
• Ceva Santé Animale
• Colorado Serum Company
• Elanco Animal Health Incorporated
• HIPRA S.A.
• Indian Immunologicals
• Merck
• biogénesis Bagó
• Vaxxinova (EW Group)
• Virbac
• Zoetis
  
• Boehringer Ingelheim

Boehringer Ingelheim is a key player in the global swine vaccine market, delivering innovative, science-driven solutions that combine advanced immunology with practical on-farm application. With a strong global presence and a commitment to sustainable livestock production, Boehringer Ingelheim continues to set new benchmarks in swine health, driving improvements in productivity, animal welfare, and biosecurity across diverse production systems. For instance, in September 2025, Boehringer Ingelheim introduced INGELVAC CIRCOFLEX AD in the U.S., the first swine vaccine to combine PCV2a and PCV2d antigens in a single dose. Designed to address the growing prevalence of PCV2d, the vaccine enhances herd health, reduces co-infections, and supports producer profitability in a shifting disease landscape.

• Merck

Merck & Co., Inc. is a prominent player in the global swine vaccine market, offering a robust portfolio of products targeting key swine diseases such as porcine circovirus (PCV2), mycoplasma hyopneumoniae, PRRS, and Lawsonia intracellularis. Its swine vaccine line includes well-established brands that utilize advanced technologies, including inactivated and RNA-based platforms, to deliver effective, tailored protection. Merck’s global manufacturing and distribution network ensures consistent supply and accessibility across major livestock-producing regions.

• Zoetis

Zoetis is a global provider of swine vaccines, offering a diverse and scientifically backed portfolio that addresses major swine diseases. The company focuses on developing combination vaccines that reduce animal handling stress and improve vaccination efficiency, helping producers streamline herd health management. With a strong emphasis on innovation, Zoetis continues to enhance vaccine delivery technologies and optimize disease prevention strategies.

Swine Vaccines Industry News

• In September 2025, Boehringer Ingelheim launched INGELVAC CIRCOFLEX AD in the U.S., the first swine vaccine to combine PCV2a and PCV2d antigens in a single dose. This innovative vaccine delivers rapid immunity within two weeks and offers protection for at least six months. Specifically developed to combat the increasing prevalence of PCV2d, it strengthens herd health, minimizes co-infections, and enhances producer profitability in an evolving disease environment. This strategic product introduction is expected to provide Boehringer Ingelheim with a significant competitive advantage in the swine health market.
  
• In April 2025, Virbac launched a new 2-in-1 swine vaccine in France that protects gilts and sows against leptospirosis and porcine parvovirus. By combining two protections in a single dose, the vaccine simplifies reproductive disease prevention, enhances herd health, and improves vaccination efficiency. This launch aligns with Virbac’s strategy to offer comprehensive and effective preventive solutions to veterinarians and producers across Europe.
  
• In October 2024, Ceva Santé Animale received European marketing authorization for Cirbloc M Hyo, a combination vaccine developed to protect pigs against Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae. The single-dose formulation provides extended protection throughout the fattening period, simplifying respiratory disease management in swine. This regulatory milestone marked a significant step for Ceva, reinforcing its dedication to innovation in animal health and strengthening its competitive position in the European swine vaccine market.
  
• In June 2023, Merck Animal Health launched Circumvent CML, a first-of-its-kind 3-in-one swine vaccine at the World Pork Expo in Des Moines, Iowa. The vaccine combines protection against PCV-2a, PCV-2d, Mycoplasma hyopneumoniae, and Lawsonia intracellularis in a single 2 cc dose for pigs aged three weeks or older. Built on proven antigens and adjuvants, it reduces stress, labor, and handling errors.
  

The swine vaccines market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Live attenuated vaccines
• Inactivated/killed vaccines
• Viral vector vaccines
• mRNA vaccines
• Other vaccines

Market, By Application

• Bacterial infections
• Viral infections
• Parasitic infections
• Other applications

Market, By Route of Administration

• Injection vaccines
• Oral vaccines
• Immersion/spray vaccines

Market, By Distribution Channel

• Veterinary hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • UAE